VIRACTA

Welcome to the Brand page for “VIRACTA”, which is offered here for The mark consists of stylized word viracta.;pharmaceutical and therapeutic preparations for the treatment of patients with viral-associated cancers and other viral associated diseases and disorders; pharmaceutical products, pharmaceutical products for treating cancer; pharmaceutical products for treating viral infections; pharmaceutical products for immune reconstitution; pharmaceutical products for cell-based immunotherapy; pharmaceutical products for t-cell adoptive transfer; pharmaceutical products for cellular adoptive transfer; pharmaceutical preparations for the treatment of cancer, tumors, and hematological malignancies;the color(s) teal and green is/are claimed as a feature of the mark.;providing medical information, consultancy and advisory services; providing a website via a global computer network featuring information in the fields of cancer, viral-associated cancers and other viral associated diseases and disorders;development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines; medical research; pharmaceutical research and development services; medical research services in the field of cancer, viral-associated cancers and other viral associated diseases and disorders; research and development of biological and chemical preparations for the treatment of cancer, viral-associated cancers and other viral associated diseases and disorders; research and development of pharmaceutical products, preparations and compounds for the treatment of viral-associated cancers and other viral associated diseases and disorders; conducting clinical trials; conducting clinical trial regarding pharmaceutical preparations and drugs in the field of viral-associated cancers and other viral associated diseases and disorders; dna screening and analysis services for scientific research purposes; research and development of pharmaceutical products, preparations and compounds for t-cell adoptive transfer, immune reconstitution, and cell-based immunotherapy; research and development of pharmaceutical products, preparations and compounds for the treatment of cancer, tumors, and hematological malignancies;.

Its status is currently believed to be active. Its class is unavailable. “VIRACTA” is believed to be currently owned by “Viracta Therapeutics, Inc.”